The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19194 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Mette Abildgaard Pedersen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Bone Density, Lymphoma, Follicular. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Aarhus Universitets Forskningsfond, Steno Diabetes Center Aarhus.
Abstract (Originalsprache)
Standard CHOP treatment includes a high cumulative dose of prednisone, and studies have shown increased fracture risk following CHOP. It is unclear whether reductions in bone mineral density (BMD) are caused by glucocorticoids or by the combination with chemotherapy. Our objective was to determine the effect of obinutuzumab (G)/rituximab (R)‐bendamustine versus G/R‐CHOP on BMD in follicular lymphoma patients. Patients in this GALLIUM post hoc study were ≥60 years old and in complete remission at induction treatment completion (ITC), following treatment with G or R in combination with bendamustine or CHOP. To assess BMD, Hounsfield units (HU) were measured in lumbar vertebra L1 on annual computed tomography. Furthermore, vertebral compression fractures were recorded. Of 173 patients included, 59 (34%) received CHOP and 114 (66%) received bendamustine. At baseline, there was no difference in HU between groups. The mean HU decrease from baseline to ITC was 27.8 after CHOP and 17.3 after bendamustine, corresponding to a difference of 10.4 (95% CI: 3.2–17.6). Vertebral fractures were recorded in 5/59 patients receiving CHOP and in 2/114 receiving bendamustine. CHOP was associated with a significant greater decrease in BMD and more frequent fractures. These results suggest that prophylaxis against BMD loss should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
- Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
- Hematology and Cancer Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, UK.
ORCID-Profile: Mette Abildgaard Pedersen, Lars C Gormsen, Toby A Eyre, Marianne T Severinsen, Joachim Baech, Eldad J Dann, Tarec C El-Galaly, Paw Jensen
Förderung
- Aarhus Universitets Forskningsfond
- Steno Diabetes Center Aarhus
Zitieren
APA
Pedersen, M. A., Gormsen, L. C., Jakobsen, L. H., Eyre, T. A., Severinsen, M. T., Baech, J., Dann, E. J., Knapp, A., Sahin, D., Vestergaard, P., El-Galaly, T. C., & Jensen, P. (2024). The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. British Journal of Haematology. https://doi.org/10.1111/bjh.19194
Vancouver
Pedersen MA, Gormsen LC, Jakobsen LH, Eyre TA, Severinsen MT, Baech J, et al. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. British Journal of Haematology. 2024. doi:10.1111/bjh.19194
BibTeX
@article{Pedersen2024,
author = {Pedersen, Mette Abildgaard and Gormsen, Lars C and Jakobsen, Lasse H and Eyre, Toby A and Severinsen, Marianne T and Baech, Joachim and Dann, Eldad J and Knapp, Andrea and Sahin, Denis and Vestergaard, Peter and El-Galaly, Tarec C and Jensen, Paw},
title = {The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19194}
}
EUVIMED